Dr. Isaacs has received honoraria from Genentech/Roche, Celgene, AstraZeneca, and Pfizer; served in a consulting or advisory role for Pfizer, Caris Life Sciences, and Genentech/Roche; served on speakers' bureaus for Genentech, Celgene, Pfizer, and AstraZeneca; received research funding from Novartis, Pfizer, Genentech, and Tesaro; and has accepted travel, accommodations, and expenses provided by Caris Life Sciences. Drs. Liu and Selvam are employees of HealthCore, Inc., a wholly owned subsidiary of Anthem, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
See JNCCN.org for supplemental online content.
RomondEHPerezEABryantJ. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med2005;353:1673–1684.
Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005;353:1659–1672.
CarlsonRWAndersonBOBensingerW. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2005. Accessed January 12 2015. To view the most recent version of these guidelines visit NCCN.org.
CarlsonRWAllredDCAndersonBO. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2010. Accessed January 12 2015. To view the most recent version of these guidelines visit NCCN.org.
National Cancer Institute. Table 1.22 U.S. Complete Prevalence Counts Invasive Cancers OnlyJanuary12009. Available at: https://seer.cancer.gov/archive/csr/1975_2009_pops09/results_single/sect_01_table.22_2pgs.pdf. Accessed August 18 2016.
American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed September 22 2016.
ClarkeCAKeeganTHYangJ. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst2012;104:1094–1101.
O'NeillSCIsaacsCChaoC. Adoption of gene expression profiling for breast cancer in us oncology practice for women younger than 65 years. J Natl Compr Canc Netw2015;13:1216–1224.
Gonzalez-AnguloAMLittonJKBroglioKR. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol2009;27:5700–5706.
SlamonDJClarkGMWongSG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987;235:177–182.
Vaz-LuisILinNUKeatingNL. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat2016;159:151–162.
Reeder-HayesKPeacockHSMengK. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol2016;34:2003–2009.
FreedmanRAHughesMEOttesenRA. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer2013;119:839–846.
TsaiHTIsaacsCFuAZ. Risk of cardiovascular adverse events from trastuzumab (Herceptin) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat2014;144:163–170.
KurianAWThompsonRNGawAF. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol2007;25:634–641.
LeungWKvizhinadzeGNairNBlakelyT. Adjuvant trastuzumab in HER2-positive early breast cancer by age and hormone receptor status: a cost-utility analysis. PLoS Med2016;13:e1002067.